VTAK
Get informed when a big investor buys or sells
+ FollowOvervalued by 150.8% based on the discounted cash flow analysis.
| Market cap | $563,535.00 |
|---|---|
| Enterprise Value | $11.89 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-15.9 |
| Beta | 0.48 |
| Outstanding Shares | 2,767,440,000 |
| P/E Ratio | -0.03 |
|---|---|
| PEG | 0.05 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 8.51 |
| Enterprise Value to EBIT | -0.58 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 1.01 |
| Debt to Equity | 0.68 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Holdings and activity of institutional investors.
| Ownership % | 0.00%▼ 0.00% |
|---|---|
| Total Invested | $102,926▼ 17.76% |
| Investors Holding | 12▲ 3.00% |
No data
advanced excimer laser-based vascular and dermatological therapies we are a commercial-stage medical device company leveraging our advanced excimer laser-based platform for use in the treatment of vascular and dermatological diseases. we...